CAREFIRST F3 Wegovy

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 800-294-5979 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Wegovy.

Patie	ent Information				
Patie	nt Name:				
Patie	nt Phone:				
Patie	nt ID:				
Patie	nt Group:				
Patie	nt DOB:				
Phys	sician Information				
Phys	ician Name				
Phys	ician Phone:				
Phys	ician Fax:				
Phys	ician Addr.:				
City,	St, Zip:				
Drug	Name (select from list of drugs shown)				
	ovy (semaglutide injection) 2.4 mg/0.75 mL Wegovy (semaglutide injection) 1.7 mg/0.75 m ion) 1 mg/0.5 mL Wegovy (semaglutide injection) 0.5 mg/0.5 mL Wegovy (semaglutide				
Quar	ntity: Frequency: Strength:	_			
Rout	e of Administration: Expected Length of Therapy:				_
Diag	nosis: ICD Code:	_			
Com	ments:				
——	as shock the appropriate answer for each applicable question				
	se check the appropriate answer for each applicable question.	v		N	
1.	Will the requested drug be used with a reduced calorie diet and increased physical activity for chronic weight management?	Υ	Ц	N	ш
2.	Is the patient 18 years of age or older?	Υ		N	
3.	Has the patient completed at least 3 months of therapy with the requested drug at a stable maintenance dose?	Y		N	
4.	Has the patient lost at least 5 percent of baseline body weight OR has the patient continued to maintain their initial 5 percent weight loss? ACTION REQUIRED: If yes, then documentation is required for approval. Document the patient's weight prior to starting drug therapy for weight loss and the patient's current weight, including the dates the weights were taken:	Y		N	
5.	Has documentation of the patient's weight prior to starting drug therapy for weight loss and the patient's current weight, including the dates the weights were taken been submitted to CVS Health?	Y		N	
6.	Does the patient require MORE than the plan allowance of 1 package/4 pens of any of the following per month: A) Wegovy 0.25 mg/0.5 mL, B) Wegovy 0.5 mg/0.5 mL, C) Wegovy 1 mg/0.5 mL, D) Wegovy 1.7 mg/0.75 mL, E) Wegovy 2.4 mg/0.75 mL?	Y		N	
7.	Has the patient participated in a comprehensive weight management program that encourages behavioral modification, reduced calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy?	Y		N	
8.	Does the patient have a baseline body mass index (BMI) of less than 27 kg/m2?	Υ		N	

9.	Does the patient have a baseline body mass index (BMI) of 27 kg/m2 to less than 30 kg/m2? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that show the patient's baseline BMI.	Y	N	
10.	Have chart notes showing the patient's baseline body mass index (BMI) been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y	N	
11.	Does the patient have at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia)? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that indicate the patient's weight-related comorbid condition(s).	Y	N	
12.	Have chart notes indicating the patient's weight-related comorbid condition(s) been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y	N	
13.	Does the patient have a baseline body mass index (BMI) of 30 kg/m2 to less than 35 kg/m2? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that show the patient's baseline BMI.	Y	N	
14.	Have chart notes showing the patient's baseline body mass index (BMI) been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y	N	
15.	Does the patient have a baseline body mass index (BMI) of 35 kg/m2 to less than 40 kg/m2? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that show the patient's baseline BMI.	Υ	N	
16.	Have chart notes showing the patient's baseline body mass index (BMI) been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y	N	
17.	Does the patient have a baseline body mass index (BMI) of 40 kg/m2 or greater? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that show the patient's baseline BMI.	Υ	N	
18.	Have chart notes showing the patient's baseline body mass index (BMI) been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y	N	
19.	Does the patient require MORE than the plan allowance of 1 package/4 pens of any of the following per month: A) Wegovy 0.25 mg/0.5 mL, B) Wegovy 0.5 mg/0.5 mL, C) Wegovy 1 mg/0.5 mL, D) Wegovy 1.7 mg/0.75 mL, E) Wegovy 2.4 mg/0.75 mL?	Y	N	
20.	Is the patient 12 to 17 years of age?	Υ	N	
21.	Is the request for continuation of therapy for a patient that has successfully titrated to a stable maintenance dose?	Υ	N	
22.	Has the patient had a reduction from their baseline body mass index (BMI) OR has the patient continued to maintain their reduction in BMI from baseline? ACTION REQUIRED: If yes, then documentation is required for approval. Document the patient's BMI prior to starting drug therapy for weight loss and the patient's current BMI, including the dates the BMIs were taken:	Y	N	
23.	Has documentation of the patient's body mass index (BMI) prior to starting drug therapy for weight loss and the patient's current BMI, including the dates the BMIs were taken been submitted to CVS Health?	Y	N	
24.	Does the patient require MORE than the plan allowance of 1 package/4 pens of any of the following per month: A) Wegovy 0.25 mg/0.5 mL, B) Wegovy 0.5 mg/0.5 mL, C) Wegovy 1 mg/0.5 mL, D) Wegovy 1.7 mg/0.75 mL, E) Wegovy 2.4 mg/0.75 mL?	Y	N	
25.	Has the patient participated in a comprehensive weight management program that encourages behavioral modification, reduced calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy?	Y	N	

26.	Does the patient have a baseline body mass index (BMI) in the 95th percentile or greater standardized for age and sex (obesity)? ACTION REQUIRED: If yes, then prescriber MUST submit chart notes that show the patient's baseline BMI percentile standardized for age and sex.	Y		N		
27.	Have chart notes showing the patient's baseline body mass index (BMI) percentile standardized for age and sex been submitted to CVS Health? ACTION REQUIRED: Submit supporting documentation	Y		N		
28.	Does the patient require MORE than the plan allowance of 1 package/4 pens of any of the following per month: A) Wegovy 0.25 mg/0.5 mL, B) Wegovy 0.5 mg/0.5 mL, C) Wegovy 1 mg/0.5 mL, D) Wegovy 1.7 mg/0.75 mL, E) Wegovy 2.4 mg/0.75 mL?	Y		N		
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.						

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.